Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1Morales, JavierPatient Care (Online)
Mechanism of Action Programmed cell death protein 1 Inhibitor Antibody Identification Summary Tislelizumab is an IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of unresectable, locally advanced or metastatic esophageal squamous cell carcinoma Brand Names Tevimbra Generic Name T...
Mechanism of Action Programmed cell death 1 ligand 1 Inhibitor Antibody Identification Summary Atezolizumab is a monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. Brand Names Tecentriq, Tece...
Mechanism of action Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts.6 IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and α-1-antichymotrypsin while inhibiting production of ...
Teplizumab The risk or severity of adverse effects can be increased when Teplizumab is combined with Pentaglobin. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pentaglobin. Tetanus immune globulin, human The risk or severity of adver...
Mechanism of Action Receptor tyrosine-protein kinase erbB-2 Binder Antibody Identification Summary Trastuzumab is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Brand Names Herceptin, Herceptin Hylecta, ...
The Fab region gives rituximab its specificity for CD20, while the Fc region interacts with cell surface receptors to activate the immune system, leading to the depletion of circulating B lymphocytes 6. In regards to the mechanism of action in rheumatoid arthritis (RA), B-cells are thought to...
Anifrolumab is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.7,11 It has a long duration of action as it is given every 4 weeks.11 Patients should be counseled regarding the...
Risankizumab works to suppress the inflammatory effects of interleukin (IL)-23. It inhibits the release of pro-inflammatory cytokines and chemokines.7 In vitro, risankizumab blocked IL-17 production;5 however, risankizumab does not actually bind to IL-17.1 Mechanism of action Interleukin (IL...
Mechanism of action Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric...